본문 바로가기

약물난치성 뇌전증 환자의 약물 치료 권고사항: 2021 대한신경과학회 진료지침 뇌전증 분과 소위원회

Practical Drug Treatment Recommendations on the Drug Refractory Epilepsy Patients: 2021 Clinical Guideline Subcommittee for Epilepsy in the Korean Neurological Association

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널 순위
KCI Q2
저널
대한신경과학회지39(4) · pp.255 · 2021
피인용
KCI 1
ISSN
1225-7044

저자

  1. 신동진제1저자가천대학교
  2. 손영민삼성서울병원
  3. 정기영서울대학교
  4. 구용서서울아산병원
  5. 김대영충남대학교
  6. 서종근경북대학교
  7. 김지영부산대학교병원
  8. 송홍기교신저자한림대학교

초록

One third of the overall epilepsy population are estimated to be a drug refractory epilepsy (DRE), defined as the patients who failed to control seizure reduction, even tried two or more appropriate antiepileptic drugs (AEDs) trials. Those people need additional AEDs trials or other treatment options (resective surgery, neuromoulation, etc.). Here, we, clinical guideline committee of the Korean Neurological Association (KNA) introduce the recommendations of AEDs treatments including not only old and new AEDs currently available in Korea but also AEDs planned to be launched in the new future for DRE patients with literature review to help efficient decision of the clinician. The authors reviewed literatures and assessed efficacy and tolerability on 12 currently available and four newly introduced/or planned AEDs applied to DRE patients, published from November 2015 to July 2021. Brivaracetam, eslicarbazepine, canabidiol and cenobamate are the four AEDs that are newly introduced or planned to be launched soon. The reviewed articles are publications after November 2015, 2018 American Association of Neurology guideline, new AEDs which were introduced or planned to be launched as of 2021. All AEDs are classified based on the therapeutic rating scheme, generating recommendations. Overall 173 papers have been reviewed and analyzed for recommendation rationales. KNA introduce additional add-on treatment or conversional monotherapy guidelines on the drug refractory focal and generalized epilepsy. We hope these guidelines or recommendations to help clinical decision for the treatment of drug refractory epilepsy patients

키워드

Antiseizure medicationsDrug refractory epilepsyGuidelineRecommendation

식별자

KCI
ART002771465